Kinetics of inhibition of purified bovine neutrophil matrix metalloproteinase 9 by low-molecular-weight inhibitors

American Journal of Veterinary Research

Volumn 70, Issue 5, 2009, Pages 633-639

  Bannikov, Gregory A ^a   Lakritz, Jeffrey ^a   Premanandan, Christopher ^a   Mattoon, John S ^a,b   Abrahamsen, Eric J ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Ocala Equine Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGS 27023A; CHLORHEXIDINE; GELATIN; GELATINASE B; GELATINASE INHIBITOR; HYDROXAMIC ACID; MINOCYCLINE; PEPTIDE; PHORBOL ESTER; SB 3CT; TETRACYCLINE; UNCLASSIFIED DRUG;

ARTICLE; COW; CULTURE MEDIUM; DEGRANULATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME SUBSTRATE; FLUORESCENCE ANALYSIS; GEL FILTRATION CHROMATOGRAPHY; GELATINIZATION; IC 50; NEUTROPHIL; NONHUMAN;

ANIMALS; CALIBRATION; CATTLE; ENZYME ACTIVATION; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; KINETICS; MATRIX METALLOPROTEINASE 9; MOLECULAR WEIGHT; NEUTROPHILS; TIME FACTORS;

BOS; BOVINAE;

EID: 65749111052     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.70.5.633     Document Type: Article

References (45)

1. Ackermann MR, Brogden KA. Response of the ruminant respiratory tract to Mannheimia (Pasteurella) hemolytica. Microbes Infect 2000;2:1079-1088.
2. Allan EM, Gibbs HA, Wiseman A, et al. Sequential lesion of experimental bovine pneumonic pasteurellosis. Vet Rec 1985;117:438-442.
3. Slocombe RF, Malark J, Ingersoll R, et al. Importance of neutrophils in the pathogenesis of acute pneumonic pasteurellosis in calves. Am J Vet Res 1985;46:2253-2258.
4. Whiteley LO, Maheswaran SK, Weiss DJ, et al. Pasteurella hemolytica A1 and bovine respiratory disease: pathogenesis. J Vet Intern Med 1992;6:11-22.
5. Radi ZA, Kehrli ME Jr, Ackermann MR. Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J Vet Intern Med 2001;15:516-529.
6. Guo RF, Ward PA. Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. Free Radic Biol Med 2002;33:303-310.
7. Corry DB, Rishi K, Kanellis J, et al. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol 2002;3:347-353.
8. Li X, Zhao X, Ma S. Secretion of 92 KDa gelatinase (MMP-9) by bovine neutrophils. Vet Immunol Immunopathol 1999;67:247-258.
9. Preece G, Murphy G, Ager A. Metalloprotemase-mediated regulation of L-selectin levels on leukocytes. J Biol Chem 1996;271:11634-11640.
10. Feehan C, Darlak K, Kahn J, et al. Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. Identification with an L-selectin-alkaline phosphatase reporter. J Biol Chem 1996;271:7019-7024.
11. Ardi VC, Kupriyanova TA, Deryugina EI, et al. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A 2007;104:20262-20267.
12. Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992;267:4583-4591.
13. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGFP and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-176.
14. Liu Z, Zhou X, Shapiro SD, et al. The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000;102:647-655.
15. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as an effector in leukocyte biology. J Leukoc Biol 2001; 69:851-859.
16. Sheu BC, Hsu SM, Ho HN, et al. A novel role of metalloproteinase in cancer mediated immunosupression. Cancer Res 2001;61:237-242.
17. Bannikov GA, Mattoon JS, Abrahamsen EJ, et al. Biochemical and enzymatic characterization of purified covalent complexes of matrix metalloproteinase-9 and haptoglobin released by bovine granulocytes in vitro. Am J Vet Res 2007;68:995-1004.
18. Starr AE, Dan T, Minhas K, et al. Potential involvement of gelatinases and their inhibitors in Mannheimia haemolytica pneumonia in cattle. Infect Immun 2004;72:4393-4400.
19. Simonen-Jokinen TL, Eskelinen UM, Härtel HM, et al. Gelatinolytic matrix metalloproteinases-2 and -9 in tracheobronchial lavage fluid obtained from calves with concurrent infections of Pasteurella multocida and Mycoplasma bovirhinis. Am J Vet Res 2005;66:2101-2106.
20. Jaeger J, Liebler-Tenorio E, Kirschvink N, et al. A clinically silent respiratory infection with Chlamydophila spp in calves is associated with airway obstruction and pulmonary inflammation. Vet Res 2007;38:711-728.
21. Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002;283:L867-L873.
22. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
23. Grant GA, Goldberg GI, Wilhelm SM, et al. Activation of extracellular MMP by proteases and organomercurials. Matrix 1992;1:217-223.
24. Chapter WZ. Chapter 18: proteinases and matrix degradation. In: Kelley WN, Hams ED, Ruddy S, et al, eds. Textbook of rheumatology. 3rd ed. Philadelphia, PA: W.B. Saunders, 1989;300-321.
25. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001;2:10-19.
26. Fini ME, Cook JR, Mohan R, et al. Regulation of matrix metalloprotease gene expression. In: Parks WC, Mecham RP, eds. Matrix metalloproteinases. San Diego: Academic Press Inc, 1998;300-356.
27. Fu X, Parks WC, Heinecke JW. Activation and silencing of matrix metalloproteonases. Semin Cell Dev Biol 2008;19:2-13.
28. Bannikov GA, Karelina TV, Collier IE, et al. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem 2002;277:16022-16027.
29. Macpherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997;40:2525-2532.
30. Matter H, Schudok M, Schwab W, et al. Tetrahydroisoquinolone-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis, and structure activity relationship. Bioorg Med Chem 2002;10:3529-3544.
31. Ollivier FJ, Brooks DE, Kallberg ME, et al. Evaluation of various compounds to inhibit activity of matrix metalloproteinases in the tear film of horses with ulcerative keratitis. Am J Vet Res 2003;64:1081-1087.
32. Lee CZ, Yao JS, Huang Y, et al. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006;26:1157-1164.
33. Gendron R, Greiner D, Sorsa T, et al. Inhibition of the activities of matrix metalloproteinases 2, 8 and 9 by chlorhexidine. Clin Diagn Lab Immunol 1999;6:437-439.
34. Ikejiri M, Bernardo MM, Bonfil RD, et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 2005;280:33992-34002.
35. Carlson GP, Kaneko JJ. A procedure for granulokinetic investigation in the developing bovine using chromium 51. Proc Soc Exp Biol Med 1974;147:863-867.
36. Lakritz J, Marsh AE, Cockrell M, et al. Characterization of gelatinases in bronchoalveolar lavage fluid and gelatinases produced by alveolar macrophages isolated from healthy calves. Am J Vet Res 2004;65:163-172.
37. Bernardo MM, Brown S, Li Z-H, et al. Design, synthesis and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem 2002;277:11201-11207.
38. Vidal A, Sabatini M, Rolland-Valognes G, et al. Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases. Bioorg Med Chem 2007;15:2368-2374.
39. Yu Z, Leung MK, Ramamurthy NS, et al. HPLC determination of a chemically modified non-antimicrobial tetracycline: biological implications. Biochem Med Metab Biol 1992;47:10-20.
40. Sorsa T, Ramamurthy NS, Vernillo AT, et al. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. J Rheumatol 1998;25:975-982.
41. Trachtman H, Futterweit S, Greenwald R, et al. Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells. Biochem Biophys Res Commun 1996;229:243-248.
42. Shlopov BV, Smith GN Jr, Cole AA, et al. Differential patterns of response to doxycycline and transforming growth factor beta 1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum 1999;42:719-727.
43. Seltzer JL, Welgus HG, Jeffrey JJ, et al. The function of calcium ion in the action of mammalian collagenase. Arch Biochem Biophys 1976;173:355-361.
44. Bu CH, Pourmotabbed T. Mechanism of Ca2+-dependent activity inhuman neutrophil gelatinase B. J Biol Chem 1996;271:14308-14315.
45. Kruger A, Arlt MJR, Gerg M, et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005; 65:3523-3526.